Medical Innovation Exchange

Biogen takes nuclear option, terminating Karyopharm ALS pact after getting a look at phase 1 data


Leave a Comment

Your email address will not be published.

Leave the field below empty!

This site uses Akismet to reduce spam. Learn how your comment data is processed.